tenofovir has been researched along with medroxyprogesterone acetate in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Baxter, C; Karim, QA; Karim, SS; Sibeko, S; Yende, N | 1 |
| Baeten, JM; Balkus, JE; Bunge, K; Chirenje, ZM; Gomez, K; Hillier, SL; Marrazzo, JM; Nair, G; Noguchi, LM; Palanee-Phillips, T; Parikh, UM; Piper, JM; Ramjee, G; Richardson, BA; Selepe, P; van der Straten, A; Watts, DH | 1 |
| Agot, K; Callahan, R; Dorflinger, L; Jenkins, D; Nanda, K; Taylor, D; Van Damme, L; Wang, M | 1 |
| Brache, V; Chandra, N; Chen, BA; Doncel, GF; Kashuba, ADM; Mauck, C; Schwartz, JL; Thurman, AR; Weiner, DH | 1 |
| Beksinska, M; Brown, TT; Eneh, P; Fowler, MG; Isingel, E; Kabwigu, S; Kaiser, T; Kiweewa Matovu, F; Nakalega, R; Nicol, MR; Staley, C; Sykes, C | 1 |
| Achilles, SL; Chen, BA; Hendrix, CW; Marzinke, MA; Meyn, LA; Tarleton, J | 1 |
| Beksinska, ME; Brown, TT; Glenn Fowler, M; Kiwanuka, N; Kiweewa Matovu, F; Musoke, P; Nabwana, M; Pettifor, JM; Scholes, D | 1 |
| Aung, W; Bakshi, RP; Bream, JH; Bumpus, NN; Coleman, JS; Diniz, CP; Farzadegan, H; Fuchs, EJ; Hendrix, CW; Hudson, S; Marzinke, MA; Nilles, TL; Rooney, JF; Rosenblum, MA; Schwartz, GJ | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
4 trial(s) available for tenofovir and medroxyprogesterone acetate
| Article | Year |
|---|---|
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; Contraceptive Agents; Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone Acetate; Organophosphonates; Pregnancy; Pregnancy Rate; Progestins; South Africa; Tenofovir; Young Adult | 2011 |
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Topics: Adult; Cohort Studies; Contraception Behavior; Contraceptive Agents, Female; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Incidence; Medroxyprogesterone Acetate; Norethindrone; Proportional Hazards Models; Risk Factors; South Africa; Tenofovir; Young Adult | 2015 |
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Topics: Adolescent; Adult; Contraceptive Agents, Female; Delayed-Action Preparations; Drug Interactions; Emtricitabine; Female; HIV Infections; Humans; Kenya; Medroxyprogesterone Acetate; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Tests; Tenofovir; Young Adult | 2016 |
Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Contraceptive Agents, Female; Drug Interactions; Female; Healthy Volunteers; HIV Infections; Humans; Medroxyprogesterone Acetate; Menstrual Cycle; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2019 |
6 other study(ies) available for tenofovir and medroxyprogesterone acetate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Medroxyprogesterone Acetate; Microbiota; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Uganda | 2020 |
Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Middle Aged; Pilot Projects; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
Topics: Adult; Bone Density; Contraceptive Agents, Female; Female; HIV Infections; Humans; Male; Medroxyprogesterone Acetate; Prospective Studies; Tenofovir; Uganda; Young Adult | 2022 |
Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
Topics: Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Medroxyprogesterone Acetate; Tenofovir | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |